CGTLive®’s Weekly Rewind – May 17, 2024

News
Article

Review top news and interview highlights from the week ending May 17, 2024.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Liso-Cel/Breyanzi Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma

The CAR T-cell therapy was also recently approved for treating chronic lymphocytic leukemia or small lymphocytic lymphoma.

2. Kevin Campbell, PhD, on the Challenges of Gene Therapy Approaches in Advanced Muscular Dystrophy

The Howard Hughes Investigator at the University of Iowa discussed his mouse model research into the pathophysiology of muscular dystrophy and how it relates to gene therapy approaches.

3. AADC Deficiency Gene Therapy up For FDA Priority Review

Eladocagene exuparvovec is approved in the United Kingdom and European Union under the name Upstaza.

4. Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma

The research trainee at Brigham and Women’s Hospital discussed developing RNA constructs to aid with RNA interference.

5. Verve Therapeutics Doses First Patient in Phase 1b Trial for Gene Therapy VERVE-102

VERVE-102 is intended to reduce LDL-C in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration
Jeffrey Chamberlain, PhD, on Continuing the Marathon of Muscular Dystrophy Research
N. Nora Bennani, MD, on Diving Deeper Into T-Cell Lymphomas
© 2024 MJH Life Sciences

All rights reserved.